VanEck Biotech ETF
BBH
112 hedge funds and large institutions have $123M invested in VanEck Biotech ETF in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 12 closing their positions.
103% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $1.19M
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
2.49% more ownership
Funds ownership: 32.95% → 35.44% (+2.5%)
1% more funds holding
Funds holding: 111 → 112 (+1)
1% less capital invested
Capital invested by funds: $124M → $123M (-$819K)
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Ascent Advisors
Mankato,
Minnesota
|
+$11.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.93M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.83M |
| 4 |
CCA
Conservest Capital Advisors
Wynnewood,
Pennsylvania
|
+$729K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$667K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.03M |
| 2 |
Two Sigma Investments
New York
|
-$1.1M |
| 3 |
LPL Financial
San Diego,
California
|
-$1.01M |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$847K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$690K |
BBH Hedge Fund Activity: Q1 2026 in Review
112 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2026, worth a combined $123M — down 0.66% from $124M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BBH positions and 12 closed out — a net gain of 4 holders — while 21 added to existing stakes and 25 trimmed.
The largest buyer was Ascent Advisors, opening a new position worth an estimated $11.5M. The largest seller was Morgan Stanley, cutting an estimated $5.03M.
- 112 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2026, up from 111 in Q4 2025.
- Funds reported $123M of VanEck Biotech ETF stock for Q1 2026, down 0.66% quarter-over-quarter.
- 16 funds opened new VanEck Biotech ETF positions in Q1 2026 and 12 closed out, a net change of +4 holders.
- The largest VanEck Biotech ETF buyer in Q1 2026 was Ascent Advisors, an estimated $11.5M added.
- The largest VanEck Biotech ETF seller in Q1 2026 was Morgan Stanley, an estimated $5.03M sold.
Based on aggregated 13F filings for Q1 2026.